Heart and systemic sclerosis-findings from a national cohort study.

coronary disease heart diseases prognosis survival analyses systemic sclerosis

Journal

Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501

Informations de publication

Date de publication:
07 Nov 2023
Historique:
accepted: 14 10 2023
received: 03 04 2023
revised: 03 10 2023
medline: 9 11 2023
pubmed: 9 11 2023
entrez: 9 11 2023
Statut: aheadofprint

Résumé

Heart involvement is one of the leading causes of death in systemic sclerosis (SSc). The prevalence of SSc-related cardiac involvement is poorly known. Our objective was to investigate the prevalence and prognosis burden of different heart diseases in a nationwide cohort of patients with SSc. We used data from a multicentric prospective study using the French SSc national database. Focusing on SSc-related cardiac involvement, we aimed to determine its incidence and risk factors. Over the 3528 patients with SSc 312 (10.9%) had SSc-related cardiac involvement at baseline. They tended to have a diffuse SSc subtype more frequently, more severe clinical features, and presented more cardiovascular risk factors. From the 1646 patients available for follow-up analysis, SSc-related cardiac involvement was associated with an increased risk of death. There was no significant difference in overall survival between SSc-related cardiac involvement, ischaemic heart disease or pulmonary arterial hypertension. Regarding survival analysis, 98 patients developed SSc-related cardiac involvement at five years (5-year event rate: 11.15%). Regarding reduced LVEF < 50% and left ventricular diastolic dysfunction, the 5-year event rate was 2.49% and 5.84% respectively. Pericarditis cumulative incidence at five years was 3%. Diffuse SSc subtype was a risk factor for SSc-related cardiac involvement and pericarditis. Female sex was associated with less left ventricular diastolic dysfunction incidence. Our results describe the incidence and prognostic burden of SSc-related cardiac involvement at a large scale, with gender and diffuse SSc subtype as risk factors. Further analyses should assess the potential impact of treatment on these various cardiac outcomes.

Identifiants

pubmed: 37944039
pii: 7379680
doi: 10.1093/rheumatology/kead599
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Alexis F Guédon (AF)

Sorbonne Université, APHP, Service de Médecine Interne, Département Hospitalo-Universitaire Inflammation-Immunopathologie-Biotherapie (DMU i3), Paris, France.
Sorbonne Université, Institut National de la Santé et de la Recherche Médicale, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.

Fabrice Carrat (F)

Sorbonne Université, Institut National de la Santé et de la Recherche Médicale, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.
Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, Unité de Santé Publique, Paris, France.

Luc Mouthon (L)

Department of Internal Medicine, Université Paris Descartes, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.

David Launay (D)

Department of Internal Medicine and Clinical Immunology, Center de Référence des maladies Autoimmunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), CHU Lille, University of Lille, Lille, France, University of Lille, U1286 - INFINITE-Institute for Translational Research in Inflammation, Lille F-59000, France; INSERM, Lille, France.

Benjamin Chaigne (B)

Department of Internal Medicine, Université Paris Descartes, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.

Grégory Pugnet (G)

Department of Internal Medicine and Clinical Immunology, Centre for Clinical Investigation (CIC BT 1436), University Hospital of Toulouse, Toulouse, France.

Jean-Christophe Lega (JC)

Service de médecine interne et vasculaire, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France; Université de Lyon, Université Lyon 1, CNRS, Laboratoire de Biométrie et Biologie Evolutive UMR 5558, Villeurbanne, France; Lyon immunopathology FEderation (LIFE), Hospices Civils de Lyon, Lyon, France.

Arnaud Hot (A)

Department of Internal Medicine, Edouard Herriot University Hospital, Hospices Civils de Lyon, Université Claude, Bernard-Lyon 1, Lyon, France.

Vincent Cottin (V)

National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, UMR 754, INRAE, Claude Bernard University, Lyon 1, Lyon, France.

Christian Agard (C)

Internal Medicine Department, Nantes Université, CHU Nantes, 1 place Alexis Ricordeau, Nantes, France.

Yannick Allanore (Y)

Department of Rheumatology, Université de Paris, Cochin Hospital, Paris, France, INSERM U1016, Institut Cochin, CNRS UMR8104, Paris, France.

Anne-Laure Fauchais (AL)

Department of Internal Medicine, Limoges University Hospital, CEDEX, Limoges, France.

Patrick Jego (P)

Department of Internal Medicine and Clinical Immunology, Rennes University Hospital, Rennes, France, Univ Rennes, Rennes University Hospital, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, Rennes, France.

Robin Dhote (R)

Sorbonne Paris Nord University, Service de Médecine Interne, Hôpital Avicenne, Bobigny, France.

Thomas Papo (T)

Department of Internal Medicine, Université de Paris, Assistance Publique-Hôpitaux de Paris, Bichat Hospital, Paris, France.

Emmanuel Chatelus (E)

Rheumatology Department, Strasbourg University Hospital, East and South-West national reference center for auto-immune diseases, Strasbourg, France.

Bernard Bonnotte (B)

Department of Internal Medicine, Centre Hospitalier Universitaire Dijon-Bourgogne, Dijon, France.

Jean-Emmanuel Khan (JE)

Department of Internal Medicine, Hôpital Ambroise Paré, Université Versailles-Saint Quentin-en-Yvelines, Boulogne-Billancourt, France.

Elisabeth Diot (E)

Department of Internal Medicine and Clinical Immunology, Regional Competence Center for Systemic and Autoimmune Rare Diseases, Bretonneau Hospital, Tours, Tours, France.

Boris Bienvenu (B)

Department of Internal Medicine, Caen University Hospital, CEDEX 9, Caen, France.

Nadine Magy-Bertrand (N)

Department of Internal Medicine, Besancon University Hospital, Besancon, France.

Viviane Queyrel (V)

Pasteur 2 Hospital, Department of Rheumatology, Cote d'Azur University, Nice University Hospital, Nice, France.

Alain Le Quellec (A)

Department of Internal Medicine, CHU Saint-Eloi, Montpellier, France.

Pierre Kieffer (P)

Internal Medicine, CH Mulhouse, Mulhouse, Grand Est.

Zahir Amoura (Z)

Département d'Immunologie, Sorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, Paris, France.

Jean-Robert Harlé (JR)

Internal Medicine Department, Assistance Publique Hôpitaux de Marseille (AP-HM), Marseille, France.

Jean-Baptiste Gaultier (JB)

Service de Médecine Interne, Hôpital Nord, Centre Hospitalier universitaire de St Etienne, saint Etienne, France.

Marie-Hélène Balquet (MH)

Department of Internal Medicine, Lens Hospital, Lens, France.

Denis Wahl (D)

Department of Vascular Medicine, Referral Center for Rare Vascular Diseases, Centre Hospitalier Régional Universitaire de Nancy, Vandoeuvre-lès-Nancy, France.

Olivier Lidove (O)

Department of Internal Medicine, Groupe Hospitalier Diaconesses-Croix Saint-Simon, Paris, France.

Olivier Fain (O)

Sorbonne Université, APHP, Service de Médecine Interne, Département Hospitalo-Universitaire Inflammation-Immunopathologie-Biotherapie (DMU i3), Paris, France.

Arsène Mékinian (A)

Sorbonne Université, APHP, Service de Médecine Interne, Département Hospitalo-Universitaire Inflammation-Immunopathologie-Biotherapie (DMU i3), Paris, France.

Eric Hachulla (E)

Department of Internal Medicine and Clinical Immunology, Center de Référence des maladies Autoimmunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), CHU Lille, University of Lille, Lille, France; University of Lille, U1286 - INFINITE-Institute for Translational Research in Inflammation, Lille F-59000, France; INSERM, Lille, France.

Sebastien Rivière (S)

Sorbonne Université, APHP, Service de Médecine Interne, Département Hospitalo-Universitaire Inflammation-Immunopathologie-Biotherapie (DMU i3), Paris, France.

Classifications MeSH